Clostridium News and Research

RSS

Xenex offers room disinfection devices to hospitals hit by Hurricane Sandy

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it is making its room disinfection devices available to hospitals affected by Hurricane Sandy.

3 Nov 2012

Researchers figure out 3D shape of promising TB drug target

Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.

26 Oct 2012

CUMC researchers develop first true mouse model of typhoid infection

Columbia University Medical Center (CUMC) researchers have created the first true mouse model of typhoid infection. The development promises to advance the study of typhoid and the creation of new vaccines against the infection, which remains a major health threat in developing countries.

26 Oct 2012

New method of oral vaccination could help boost immunity to TB, influenza and C. difficile

Scientists at Royal Holloway, University of London have developed a pioneering new method of oral vaccination which could help boost immunity to TB and influenza, as well as prevent C. difficile for which there is currently no vaccine.

25 Oct 2012

C. diff infections on the rise among children, elderly

Clostridium difficile infections are becoming more common and more severe in hospitalized children and the elderly, in large part due to greater use of antibiotics, Mayo Clinic researchers report in studies being presented at the American College of Gastroenterology annual meeting.

23 Oct 2012

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

A novel therapy that uses donated human stool to treat the deadly and contagious C.diff infection is safe and highly effective, according to a Henry Ford Hospital study.

20 Oct 2012

Xenex Healthcare Services receives GSA contract to purchase room disinfection systems

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it has been awarded a U.S. General Services Administration (GSA) contract, making it even easier for federal agencies (including Veterans Affairs hospital systems) to purchase Xenex's room disinfection systems.

11 Oct 2012

Progress toward preventing initial and recurrent episodes of C. diff infection

Surgeons are making progress toward preventing initial and recurrent episodes of clostridium difficile colitis (C. difficile or C. diff), a vicious bacterial infection that is estimated to affect about 336,000 people each year, typically patients on antibiotics.

6 Oct 2012

New tools can help track healthcare-associated infections in nursing homes

The Society for Healthcare Epidemiology of America (SHEA) and Centers for Disease Control and Prevention (CDC) have each released new tools and information to help track deadly healthcare-associated infections (HAIs) in nursing homes and other long-term care settings.

19 Sep 2012

Xenex's pulsed xenon UV more effective than bleach in decontaminating C. diff surfaces

Healthcare associated infections (also referred to as HAIs or hospital acquired infections) are the fourth leading cause of death in the United States, costing more than $30 billion each year. Evidence continues to mount that hospital cleanliness plays a role in the spread of HAIs, which are caused by deadly pathogens such as C. diff, MRSA, VRE and Acinetobacter.

19 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

Study assesses hand contamination of healthcare workers after disinfection procedures

New research demonstrates that daily cleaning of high-touch surfaces in isolation rooms of patients with Clostridium difficile (C. difficile) or methicillin-resistant Staphylococcus aureus (MRSA) significantly reduces the rate of the pathogens on the hands of healthcare personnel.

15 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Clinical trial to test whether fecal transplantation is effective in treating relapsing C. difficile

For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.

22 Aug 2012

Wound dressing containing ionic silver capable of killing multidrug-resistant organisms

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of multidrug-resistant organisms (MDROs), commonly referred to as 'superbugs.' The study results were published in the August issue of the International Wound Journal.

13 Aug 2012